Skip to main content
. Author manuscript; available in PMC: 2020 Feb 19.
Published in final edited form as: Biochem Biophys Res Commun. 2019 Jan 17;509(4):1034–1040. doi: 10.1016/j.bbrc.2019.01.050

Figure 4. PF-271 treatment reduces VCAM-1 expression in PLNs and B16F10 metastatic potential to PLNs.

Figure 4.

Mice were injected with B16F10-RFP cells and then treated with either vehicle or PF-271 (50 mg/kg, twice daily) via oral gavage starting on day 8. Tumor PLNs were collected on day 14. (A) Shown are immunostaining of tumor PLNs for VCAM-1 (green), B16F10-RFP (red), and DAPI. Merge 1; VCAM-1 and B16F10-RFP. Merge 2; VCAM-1, B16F10-RFP, and DAPI. Scale bar, 200 μm (n=4). (B and C) Fluorescent intensity (FI) of VCAM-1 (green, B) and FI of RFP (red, C) was measured using Image J. Scale bar, 200 μm. (± S.D., n=9). ** p<0.005.